Table 1. Clinical and laboratory... | American Society of Hematology

Table 1.

Clinical and laboratory features of patients studied

Patient ID	Age (y)/sex	Clinical features^†	Duration (mo)^‡	GPI-deficient clone (%)^*			B cell count/ (10⁹/L)^1-153
Patient ID	Age (y)/sex	Clinical features^†	Duration (mo)^‡	Granulocytes	RBCs	B cells	B cell count/ (10⁹/L)^1-153
PNH006	45/F	Hemolytic/thrombotic	195	99.4	32.9	0.8	0.18
PNH008	32/F	Hemolytic	144	0.0	0.0	13.8	0.07
PNH018	31/M	Hypoplastic	96	1.9	0.4	4.6	0.04
PNH033	36/F	Hemolytic	200	99.7	57.8	54.4	0.02
PNH042	56/M	Hemolytic	144	97.7	60.6	2.2	0.10
PNH043	46/M	Hypoplastic	60	99.3	49.7	0.5	0.03
PNH048	30/F	Hypoplastic	59	27.7	13.3	0.1	0.06
PNH055	45/F	Hypoplastic	45	80.2	17.1	3.7	0.06
PNH056	32/M	Hemolytic	78	31.3	34.8	9.6	0.10
PNH064	24/M	Hypoplastic	34	29.7	13.1	3.1	0.04
PNH065	23/F	Hypoplastic/MDS	0	79.2	40.9	6.5	0.14
PNH069	50/F	Hemolytic	2	93.3	24.3	28.6	0.06
PNH075	31/M	Hypoplastic	25	9.6	8.7	4.7	0.09
PNH077	52/M	Hemolytic	40	98.4	36.5	3.8	0.10
PNH090	37/F	Hemolytic	30	93.5	54.3	6.0	0.01
PNH094	34/F	Hypoplastic	0	0.9	3.5	0.2	0.24
PNH098	32/M	Hemolytic/thrombotic	93	57.3	36.0	3.5	0.02
PNH102	78/M	Hypoplastic	0	55.5	5.2	1.2	0.12
PNH104	69/M	MDS	480	—	—	1.3	0.02
PNH105	36/M	Hemolytic to hypoplastic	6	77.0	28.3	2.5	0.02
PNH107	37/M	Thrombotic	8	94.6	37.6	1.8	0.07
PNH110	56/M	Hemolytic	18	75.9	51.8	5.6	0.22
PNH111	43/F	Hemolytic	10	95.2	47.9	14.7	0.03
PNH115	52/F	Hypoplastic	14	5.0	1.1	0.2	0.33
PNH119	45/F	Thrombotic	0	15.3	6.8	4.0	0.03
PNH120	51/F	Hemolytic	11	83.3	45.8	1.6	0.03
PNH121	42/F	Hemolytic	0	92.6	31.3	0.6	0.05
PNH122	23/F	Hemolytic	12	57.7	23.3	2.0	0.12
PNH124	18/M	Hemolytic	92	72.3	55.0	2.7	0.07

Patient ID	Age (y)/sex	Clinical features^†	Duration (mo)^‡	GPI-deficient clone (%)^*			B cell count/ (10⁹/L)^1-153
Patient ID	Age (y)/sex	Clinical features^†	Duration (mo)^‡	Granulocytes	RBCs	B cells	B cell count/ (10⁹/L)^1-153
PNH006	45/F	Hemolytic/thrombotic	195	99.4	32.9	0.8	0.18
PNH008	32/F	Hemolytic	144	0.0	0.0	13.8	0.07
PNH018	31/M	Hypoplastic	96	1.9	0.4	4.6	0.04
PNH033	36/F	Hemolytic	200	99.7	57.8	54.4	0.02
PNH042	56/M	Hemolytic	144	97.7	60.6	2.2	0.10
PNH043	46/M	Hypoplastic	60	99.3	49.7	0.5	0.03
PNH048	30/F	Hypoplastic	59	27.7	13.3	0.1	0.06
PNH055	45/F	Hypoplastic	45	80.2	17.1	3.7	0.06
PNH056	32/M	Hemolytic	78	31.3	34.8	9.6	0.10
PNH064	24/M	Hypoplastic	34	29.7	13.1	3.1	0.04
PNH065	23/F	Hypoplastic/MDS	0	79.2	40.9	6.5	0.14
PNH069	50/F	Hemolytic	2	93.3	24.3	28.6	0.06
PNH075	31/M	Hypoplastic	25	9.6	8.7	4.7	0.09
PNH077	52/M	Hemolytic	40	98.4	36.5	3.8	0.10
PNH090	37/F	Hemolytic	30	93.5	54.3	6.0	0.01
PNH094	34/F	Hypoplastic	0	0.9	3.5	0.2	0.24
PNH098	32/M	Hemolytic/thrombotic	93	57.3	36.0	3.5	0.02
PNH102	78/M	Hypoplastic	0	55.5	5.2	1.2	0.12
PNH104	69/M	MDS	480	—	—	1.3	0.02
PNH105	36/M	Hemolytic to hypoplastic	6	77.0	28.3	2.5	0.02
PNH107	37/M	Thrombotic	8	94.6	37.6	1.8	0.07
PNH110	56/M	Hemolytic	18	75.9	51.8	5.6	0.22
PNH111	43/F	Hemolytic	10	95.2	47.9	14.7	0.03
PNH115	52/F	Hypoplastic	14	5.0	1.1	0.2	0.33
PNH119	45/F	Thrombotic	0	15.3	6.8	4.0	0.03
PNH120	51/F	Hemolytic	11	83.3	45.8	1.6	0.03
PNH121	42/F	Hemolytic	0	92.6	31.3	0.6	0.05
PNH122	23/F	Hemolytic	12	57.7	23.3	2.0	0.12
PNH124	18/M	Hemolytic	92	72.3	55.0	2.7	0.07

GPI-deficient clones as measured by flow cytometry.

Hypoplastic patients defined by an absence of macroscopic hemoglobinuria.

Time in months since the onset of PNH.

Reference ranges: B cells 0.06-0.6 × 10⁹/L.